Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27218889 | 0.80 | MAPT (0.48) | KDM4EHPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29808208 | 0.80 | HPGD (0.54) | KDM4EHPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29808182 | 0.77 | NOTUM (0.48) | KDM4EHPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5695138 | 0.74 | HSD17B10 (0.65) | KDM4ENPC1RAB9ASMN1; SMN2ALOX15 | |
| SCHEMBL266619 | 0.74 | KDM4E (0.66) | KDM4EHPGDNPC1RAB9AHRH3 | |
| SCHEMBL6568991 | 0.72 | KDM4E (0.59) | KDM4EHPGDNPC1RAB9AHRH3 | |
| SCHEMBL29807808 | 0.72 | TSHR (0.61) | NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL9316495 | 0.71 | MAPT (0.53) | KDM4EHPGDMAPTPOLB | |
| SCHEMBL29808180 | 0.70 | SMN1; SMN2 (0.57) | KDM4EHPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4037331 | 0.70 | KDM4E (0.69) | KDM4EHPGDNPC1RAB9AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220274968-A1 | Oxazole And Oxadiazole Derivatives Useful As Agonists Of Free Fatty Acid Receptor 1 | GBIOTECH S.À.R.L. (CH) | 2022-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220274968-A1 | Oxazole And Oxadiazole Derivatives Useful As Agonists Of Free Fatty Acid Receptor 1 | FFAR2, FFAR1, FFAR3 | KDM4E 3951/4885HPGD 1443/4885NPC1 2356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.